BioCryst Pharma (BCRX) Posts Q4 Loss of 9c/Share

February 26, 2014 6:53 AM

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found